1.025

4.06% 0.04

After Hours: 1.04 0.015 +1.46%

Phio Pharmaceuticals Corp (PHIO)

Overview News Price History Financials Why PHIO Down? Discussions Forecast Stock Split

Phio Pharmaceuticals Corp stock is traded at $1.025, with a volume of 219.60K. It is up +4.06% in the last 24 hours and down -7.66% over the past month. Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.

Previous Close:

$0.985

Open:

$1.02

24h Volume:

219.60K

Relative Volume:

1.27

Market Cap:

$11.91M

Revenue:

Net Income/Loss:

$-10.93M

P/E Ratio:

-0.7129

EPS:

-1.4378

Net Cash Flow:

$-10.72M

1W Performance:

-1.44%

1M Performance:

-7.66%

6M Performance:

+0.49%

1Y Performance:

-56.38%

1-Day Range:

$1.01

$1.05

1-Week Range:

$0.9598

$1.06

52-Week Range:

$0.8127

$4.1899

Phio Pharmaceuticals Corp Stock (PHIO) Company Profile

Name

Phio Pharmaceuticals Corp

Sector

Healthcare (1095)

Industry

Biotechnology (614)

Phone

(508) 767-3861

Address

411 SWEDELAND ROAD, KING OF PRUSSIA, MA

Employee

Twitter

@phio_pharma

Next Earnings Date

2026-08-13

Latest SEC Filings

PHIO's Discussions on Twitter

Compare PHIO vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PHIO Phio Pharmaceuticals Corp	1.025	11.27M	0	-10.93M	-10.72M	-1.4378
VRTX Vertex Pharmaceuticals Inc	496.73	124.70B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	623.54	66.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	927.77	55.17B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.03	38.90B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	187.28	38.71B	742.00K	-1.37B	-1.07B	-7.0731

Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-05-25	Resumed	H.C. Wainwright	Buy
Aug-05-20	Initiated	H.C. Wainwright	Buy

Phio Pharmaceuticals Corp Stock (PHIO) Latest News

Jun 29, 2026

Phio Pharmaceuticals CEO Robert Bitterman buys $9,900 in stock - Investing.com

Jun 29, 2026

[Form 4] Phio Pharmaceuticals Corp. Insider Trading Activity - Stock Titan

Jun 29, 2026

Form 4 Phio Pharmaceuticals Corp For: 29 June By Investing.com - Investing.com South Africa

Jun 29, 2026

Phio Pharmaceuticals CEO Robert Bitterman buys $9,900 in stock By Investing.com - Investing.com South Africa

Jun 29, 2026

PHIO: PH-762 achieved strong safety and efficacy, with INTASYL poised for broader clinical impact - TradingView

Jun 29, 2026

PHIO: PH-762 achieved 85% response with no serious adverse events; next trial planned for early next year - TradingView

Jun 29, 2026

Jun 28, 2026

Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026 - TMX Newsfile

Jun 28, 2026

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series - TMX Newsfile

Jun 28, 2026

Jun 26, 2026

Phio CEO to pitch INTASYL cancer platform in June 30 webcast - Stock Titan

Jun 26, 2026

Jun 25, 2026

Phio Pharmaceuticals (PHIO) Life Sciences Virtual Investor Forum Summary - Quartr

Jun 25, 2026

Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762 - EIN News

Jun 25, 2026

Phio Pharmaceuticals begins commercial-scale production of PH-762 By Investing.com - Investing.com South Africa

Jun 24, 2026

Phio Pharmaceuticals begins commercial-scale production of PH-762 - Investing.com

Jun 24, 2026

Phio’s PH-762 clears a manufacturing step toward its next trial - Stock Titan

Jun 24, 2026

Jun 23, 2026

Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026 - The Des Moines Register

Jun 23, 2026

Jun 17, 2026